Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yun Fan

Showing results (911-920 of 920) with videos related to

Pageof 92
Sort By:
You have reached the last page of results.This site can display upto 920 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)Zhijie Wang, Lin Wu, Baolan Li, et al.
Cancer Cell|September 10, 2024
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancerJiachen Xu, Rui Wan, Yiran Cai, et al.
JAMA|May 31, 2024
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial, Wenfeng Fang, Yuanyuan Zhao, et al.
JAMA|June 17, 2026
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial, Wenfeng Fang, Yuanyuan Zhao, et al.
Translational Lung Cancer Research|July 28, 2018
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panelYi-Long Wu, Chang-Li Wang, Mei-Lin Liao, et al.
ESMO Open|August 30, 2017
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panelYi-Long Wu, Chang-Li Wang, Yan Sun, et al.
Signal Transduction and Targeted Therapy|December 23, 2024
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trialJia Zhong, Kailun Fei, Lin Wu, et al.
Cancer Cell|March 4, 2022
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trialZi-Xian Wang, Chengxu Cui, Jun Yao, et al.
Thoracic Cancer|November 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancerDingzhi Huang, Gen Lin, Qian Chu, et al.
Thoracic Cancer|January 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancerGen Lin, Zhijie Wang, Qian Chu, et al.
Pageof 92

Showing results (911-920 of 920) with videos related to

Sort By:
Pageof 92
You have reached the last page of results.This site can display upto 920 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)Zhijie Wang, Lin Wu, Baolan Li, et al.
Cancer Cell|September 10, 2024
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancerJiachen Xu, Rui Wan, Yiran Cai, et al.
JAMA|May 31, 2024
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial, Wenfeng Fang, Yuanyuan Zhao, et al.
JAMA|June 17, 2026
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial, Wenfeng Fang, Yuanyuan Zhao, et al.
Translational Lung Cancer Research|July 28, 2018
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panelYi-Long Wu, Chang-Li Wang, Mei-Lin Liao, et al.
ESMO Open|August 30, 2017
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panelYi-Long Wu, Chang-Li Wang, Yan Sun, et al.
Signal Transduction and Targeted Therapy|December 23, 2024
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trialJia Zhong, Kailun Fei, Lin Wu, et al.
Cancer Cell|March 4, 2022
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trialZi-Xian Wang, Chengxu Cui, Jun Yao, et al.
Thoracic Cancer|November 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancerDingzhi Huang, Gen Lin, Qian Chu, et al.
Thoracic Cancer|January 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancerGen Lin, Zhijie Wang, Qian Chu, et al.
Pageof 92